| |
|
|
|
|
|
 |
| |
|
¾Æ»çÄÝÁ¾à500mg(¸Þ»ì¶óÁø) Asacol Suppositories 500mg
|
Àü¹®ÀǾàǰ | ±Þ¿©
|
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
 |
Á¦Ç°º° ¿¬·É±Ý±â °í½Ã |
|
|
| ¼ººÐ¸í |
¼ººÐÄÚµå |
ƯÁ¤¿¬·É |
°í½Ã¹øÈ£ |
°í½ÃÀÏÀÚ |
ºñ°í |
| mesalazine |
190803CSP |
4 ÁÖ ¹Ì¸¸ |
20110110 |
2011-06-28 |
|
|
|
 |
Á¦Ç°º° ÀӺαݱ⠰í½Ã |
|
|
|
1µî±Þ: ¿øÄ¢Àû »ç¿ë±Ý±â / 2µî±Þ: ¸íÈ®ÇÑ ÀÓ»óÀû ±Ù°Å ¶Ç´Â »çÀ¯°¡ ÀÖ´Â °æ¿ì ºÎµæÀÌÇÏ°Ô »ç¿ë / Mµî±Þ: ÀÓ»óÀû»óȲ¿¡ µû¶ó 1µî±Þ ¶Ç´Â 2µî±ÞÀ¸·Î ºÐ·ùµÇ´Â ¼ººÐ
| ¼ººÐ¸í |
¼ººÐÄÚµå |
±Ý±âµî±Þ |
°í½Ã¹øÈ£ |
°í½ÃÀÏÀÚ |
ºñ°í |
| mesalazine |
190803CSP |
2 |
20170086 |
20171106 |
"(Àüü) ÀӺο¡ ´ëÇÑ ¾ÈÀü¼º ¹ÌÈ®¸³.(Á¤Á¦) Á¶»êÀ², »ç»êÀ², ÀúüÁß Ãâ»êÀ²ÀÇ Áõ°¡, ½Å»ý¾Æ¿¡¼ ½ÅºÎÀü ¹ß»ý(¼¹æÁ¤,°ú¸³Á¦,°üÀåÁ¦) Á¶»êÀ², »ç»êÀ², ÀúüÁß Ãâ»êÀ²ÀÇ Áõ°¡, ½Å»ý¾Æ¿¡¼ Ç÷¾× Áúȯ(¹üÇ÷±¸°¨¼ÒÁõ, ¹éÇ÷±¸°¨¼ÒÁõ, Ç÷¼ÒÆÇ°¨¼ÒÁõ, ºóÇ÷), ½ÅºÎÀü µî º¸°í(Àå¿ëÁ¤) ¼±Ãµ¼º ±âÇü ¹× ±âŸ À¯ÇØÇÑ °á°ú(¹éÇ÷±¸°¨¼ÒÁõ, Ç÷¼ÒÆÇ°¨¼ÒÁõ ¹× ºóÇ÷ °°Àº Ç÷¾× Àå¾Ö »ç·Ê Æ÷ÇÔ)°¡ º¸°í(Æ÷¸») ½Å»ý¾Æ¿¡¼ Ç÷¾× Áúȯ(¹éÇ÷±¸°¨¼ÒÁõ, Ç÷¼ÒÆÇ°¨¼ÒÁõ, ºóÇ÷), ½ÅºÎÀü µî |
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
641601850[E03070081]
Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\812 ¿ø/1°³(2024.12.01)(ÇöÀç¾à°¡)
\733 ¿ø/1°³(2022.06.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ȸ°¥»öÀÇ ¹æÃßÇü Á¾à
[Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
500mg¡¿20EA |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 500¹Ð¸®±×·¥ |
20 °³ |
PTP |
8806416018507 |
8806416018521 |
|
| 500¹Ð¸®±×·¥ |
1 °³ |
PTP |
8806416018507 |
8806416018514 |
|
|
| ÁÖ¼ººÐÄÚµå |
190803CSP
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
°æÁõ ¹× ÁßµîÁõÀÇ ±Ë¾ç¼º ´ëÀå¿°(ƯÈ÷ Ç×¹®¿¡¼ 20§¯±îÁö ¹ßº´ÇÏ´Â Á÷Àå¿°, ¿øÀ§ Á÷Àå S»ó °áÀå¿°)ÀÇ ±Þ¼º¹ßÀÛ Ä¡·á ¹× Àç¹ß¿¹¹æ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
°æÁõ ¹× ÁßµîÁõÀÇ ±Ë¾ç¼º ´ëÀå¿°ÀÇ ±Þ¼º¹ßÀÛ Ä¡·á : Åë»ó ¼ºÀÎÀÇ °æ¿ì 1°³(500mg)À» 1ÀÏ 3ȸ Á÷Àå³» »ðÀÔÇÑ´Ù.
Àå±â°£ À¯Áö¿ä¹ý ¹× Àç¹ß¿¹¹æ : Åë»ó ¼ºÀÎÀÇ °æ¿ì 1ȸ 1°³(500mg)¸¦ 1ÀÏ 2ȸ Á÷Àå³» »ðÀÔÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à, ÀÌ ¾àÀÇ ¼ººÐ, »ì¸®½Ç»ê ¶Ç´Â »ì¸®½Ç»ê¿°¿¡ °ú¹ÎÁõÀÌ Àִ ȯÀÚ
2) ÁßÁõÀÇ °£Àå¾Ö ¶Ç´Â ÁßÁõÀÇ ½ÅÀå¾Ö ȯÀÚ
3) ¼Òȼº ±Ë¾ç ȯÀÚ
4) Ç÷¾×ÀÀ°íÀå¾Ö ȯÀÚ
5) 4ÁÖ ¹Ì¸¸ÀÇ ½Å»ý¾Æ ¶Ç´Â ¹Ì¼÷¾Æ(ÁÂÁ¦¿¡ ÇÑÇÔ)
|
| ½ÅÁßÅõ¿© |
1) ±â°üÁö õ½Ä ȯÀÚ
2) ´Ù¸¥ ¾à¹°¿¡ °ú¹ÎÁõÀΠȯÀÚ
3) °£Àå¾Ö ¶Ç´Â ½ÅÀå¾Ö ȯÀÚ
4) Ç÷¾×Àå¾Ö ȯÀÚ
5) ÀӺΠ¹× ¼öÀ¯ºÎ
6) 2¼¼¢¦15¼¼ ¹Ì¸¸ À¯.¼Ò¾Æ
7) °í·ÉÀÚ
8) ¼³ÆÄ»ì¶óÁø ÇÔÀ¯Á¦Á¦¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
ÀÓ»ó½ÃÇè¿¡¼ °¡Àå ÀÚÁÖ º¸°íµÇ´Â ÀÌ»ó¹ÝÀÀÀº ¼³»ç, ¿À½É, º¹Åë, µÎÅë, ±¸Åä ¹× ¹ßÁøÀÌ´Ù.
°ú¹Î¹ÝÀÀ ¹× ¾à¹°·Î ÀÎÇÑ ÀÌ»ó°í¿ÁõÀÌ °¡²û ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ±×¸®°í ¸Þ»ì¶óÁø Åõ¿©¿Í È£»ê±¸ Áõ°¡ ¹× Àü½Å Áõ»ó µ¿¹Ý ¾à¹° ¹ÝÀÀ (DRESSÁõÈıº), ½ºÆ¼ºì½º-Á¸½¼ ÁõÈıº (SJS), µ¶¼º Ç¥ÇÇ ±«»ç ¿ëÇØ (TEN)¸¦ Æ÷ÇÔÇÏ´Â ÁßÁõ ÇǺΠÀÌ»ó ¹ÝÀÀ (SCAR)°úÀÇ °ü·Ã¼ºÀÌ º¸°íµÇ¾ú´Ù.
Á÷ÀåÀ¸·Î Åõ¿© ½Ã °¡·Á¿ò, Á÷ÀåÀÇ ºÒÄè°¨, º¯À» ¸ø Âü´Â Áõ»ó °°Àº ±¹¼Ò¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÀÌ»ó¹ÝÀÀÀº ´ÙÀ½°ú °°Àº ºóµµÁ¤ÀÇ¿¡ µû¶ó ³ª¿µÇ¾ú´Ù. :
ÈçÇϰÔ(¡Ã1/100, <1/10), µå¹°°Ô(¡Ã1/10,000, <1/1,000), ¸Å¿ì µå¹°°Ô(<1/10,000), ¾Ë ¼ö ¾øÀ½.
ÀÓ»ó½ÃÇè°ú ½ÃÆÇ ÈÄ Á¶»ç¿¡¼ º¸°íµÈ ÀÌ»ó¹ÝÀÀÀº ¾Æ·¡¿Í °°´Ù.
| ±â°ü |
ÈçÇÏ°Ô (¡Ã1/100 À̰í <1/10) |
µå¹°°Ô (¡Ã1/10,000 À̰í <1/1,000) |
¸Å¿ì µå¹°°Ô (<1/10,000) |
¾Ë ¼ö ¾øÀ½ |
| Ç÷¾× ¹× ¸²ÇÁ°è ÀÌ»ó |
|
|
ºóÇ÷, Àç»ý ºÒ·®¼º ºóÇ÷, ¹«°ú¸³±¸Áõ, È£Áß±¸°¨¼ÒÁõ, ¹éÇ÷±¸°¨¼ÒÁõ(°ú¸³¹éÇ÷±¸°¨¼Ò Æ÷ÇÔ), ¹üÇ÷±¸°¨¼ÒÁõ, Ç÷¼ÒÆÇ°¨¼ÒÁõ°ú È£»ê±¸Áõ(¾Ë·¹¸£±â ¹ÝÀÀÀÇ ÀϺηÎ) |
|
| ¸é¿ª°è ÀÌ»ó |
|
|
¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀ» Æ÷ÇÔÇÏ´Â °ú¹Î¹ÝÀÀ |
|
| ½Å°æ°è ÀÌ»ó |
µÎÅë |
¾îÁö·³ |
¸»ÃʽŰæÀå¾Ö |
Ư¹ß¼º µÎ°³ ³»¾Ð Ç×Áø |
| ½ÉÀå ÀÌ»ó |
|
½É±Ù¿°* ¹× ½É³¶¿°* |
|
|
| È£Èí, ÈäºÎ ¹× Á¾°Ý ÀÌ»ó |
|
|
¾Ë·¯Áö¼º ¹× ¼¶À¯¼ºÀÇ Æó¹ÝÀÀ(È£Èí°ï¶õ, ±âħ, ±â°üÁö°æÃà, ¾Ë·¹¸£±â¼º ÆóÆ÷¿° Æ÷ÇÔ), Æó¼º È£»ê ¹éÇ÷±¸ Áõ°¡, °£Áú¼º ÆóÁúȯ, ÆóħÀ±, Æó·Å |
È丷¿° |
| ¼Òȱâ°è ÀÌ»ó |
¼³»ç, º¹Åë, ±¸¿ª, ±¸Åä, °íâ |
¾Æ¹Ð¶ó¾ÆÁ¦ Áõ°¡¿Í ±Þ¼º ÃéÀå¿°* |
´ëÀå¿° |
|
| °£´ãµµ°è ÀÌ»ó |
|
|
¾Æ¹Ì³ëÀüÀÌÈ¿¼Ò, ´ãÁóÁ¤Ã¼ Æò°¡º¯¼ö(¿¹ ; ¾ËÄ®¸®¼º ÀλêºÐÇØÈ¿¼Ò, °¨¸¶-±Û·çŸ¹ÐÀüÀÌÈ¿¼Ò ¹× ºô¸®·çºó)ÀÇ Áõ°¡, °£µ¶¼º (°£¿°*, ´ãÁó Á¤Ã¼¼º °£¿°, °£°æº¯, °£ºÎÀü Æ÷ÇÔ) |
|
| ÇǺΠ¹× ÇÇÇÏÁ¶Á÷°è ÀÌ»ó |
¹ßÁø(µÎµå·¯±â, È«¹Ý¼º ¹ßÁø Æ÷ÇÔ) |
±¤¼±°ú¹ÎÁõ** |
Å»¸ð, ¾Ë·¹¸£±â ¹ßÁø, ´ÙÇüÈ«¹Ý |
½ºÆ¼ºì½º-Á¸½¼ ÁõÈıº(SJS), µ¶¼º Ç¥ÇÇ ±«»ç ¿ëÇØ(TEN), È£»ê±¸ Áõ°¡ ¹× Àü½Å Áõ»ó µ¿¹Ý ¾à¹° ¹ÝÀÀ(DRESSÁõÈıº) |
| ±Ù°ñ°Ý°è, °áÇÕÁ¶Á÷ ¹× »À ÀÌ»ó |
|
|
±ÙÀ°Åë, °üÀýÅë, È«¹Ý¼º³¶Ã¢ÁõÈıº |
|
| ½ÅÀå ¹× ºñ´¢±â°è ÀÌ»ó |
|
|
½Å±â´É ÀÌ»ó(±Þ¼º ¹× ¸¸¼º °£Áú¼º ½Å¿°*, ½ÅÁõÈıº, ½ÅºÎÀü Æ÷ÇÔ) |
½Å°á¼®Áõ***, ¿ä º¯»ö*** |
| »ý½Ä±â°è ÀÌ»ó |
|
|
°¡¿ªÀûÀÎ Á¤ÀÚºÎÁ· |
|
| Àü½Å ¹× Åõ¿©ºÎÀ§ ÀÌ»ó |
|
|
ÀÌ»ó°í¿Áõ |
|
* ¸Þ»ì¶óÁøÀ¸·Î ÀÎÇÑ ÃéÀå¿°, °£¿°, ½É±Ù¿° ¹× ½É³¶¿°, ½Å¿°ÀÇ ¹ß»ý ±âÀüÀº ¹àÇôÁöÁö ¾Ê¾ÒÁö¸¸ ¾Ë·¹¸£±â ¶§¹®ÀÏ °¡´É¼ºÀº ÀÖÀ½.
** ±¤¼±°ú¹ÎÁõ: ±âÁ¸¿¡ ¾ÆÅäÇÇÇǺο°°ú ¾ÆÅäÇǽÀÁø°ú °°Àº ÇǺΠ»óŸ¦ Áö´Ñ ȯÀڵ鿡°Ô¼´Â º¸´Ù ÁßÁõÀÇ ¹ÝÀÀÀÌ º¸°íµÈ´Ù.
*** Ãß°¡ÀûÀÎ Á¤º¸´Â 4. ÀϹÝÀû ÁÖÀÇ Ç× Âü°í
À̿ܿ¡ º¹ºÎÆØ¸¸°¨, Æ®¸², ¸ÞÆ®Çì¸ð±Û·Îºó ¼öÄ¡ÀÇ »ó½Â, °á¸·¿°, ¸Å¿ì µå¹°°Ô û¼Ò³â ¾ç¼º µÎ°³ ³»¾Ð »ó½Â, Ç÷°üºÎÁ¾ÀÌ º¸°íµÇ¾úÀ¸¸ç, ÀÌ·ÐÀûÀ¸·Î ÀûÇ÷±¸ »êÈ °¨¼Ò°¡ ÀϾ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
´ÙÀ½ ¾à¹°°ú º´¿ëÅõ¿©½Ã ÀÌµé ¾à¹°ÀÇ ÀÛ¿ëÀ» Áõ° ¶Ç´Â °¨¼Ò½Ãų ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù. º´¿ëÅõ¿©·Î ¾Æ·¡ÀÇ »óÈ£ÀÛ¿ëÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù.
1) ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°Á¦(NSAID)³ª ¾ÆÀÚÆ¼¿ÀÇÁ¸°°ú °°ÀÌ ½ÅÀåµ¶¼ºÀ» À¯¹ßÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁø ¾à¹°°ú ÇÔ²² Åõ¿©ÇÏ¸é ½ÅÀåµ¶¼ºÀ» Áõ°¡½Ãų °¡´É¼ºÀÌ ÀÖ´Ù.
2) Äí¸¶¸°°è Ç×ÀÀ°íÁ¦ : Ç÷¾×ÀÀ°í ÀúÁöÀÛ¿ëÀ» »ó½Â½Ãų ¼ö ÀÖ´Ù(À§Àå°ü ÃâÇ÷ÀÇ À§Ç輺 Áõ°¡).
3) ºÎ½ÅÇÇÁúÈ£¸£¸ó Á¦Á¦ : À§Àå°ü ºÎÀÛ¿ë Áõ°¡.
4) ¸ÞÅ䯮·º¼¼ÀÌÆ® : ¸ÞÅ䯮·º¼¼ÀÌÆ®ÀÇ µ¶¼ºÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù.
5) Ǫ·Îº£³×½Ãµå, ¼³ÇÉÇǶóÁ¸ : ¿ä»ê¹è¼³ ÀÛ¿ëÀ» °¨¼Ò½Ãų ¼ö ÀÖ´Ù.
6) ¼³Æ÷´Ò¿ì·¹¾Æ Á¦Á¦ : ÀúÇ÷´ç¼º ÀÛ¿ëÀ» »ó½Â½Ãų ¼ö ÀÖ´Ù.
7) ½ºÇǷγë¶ôÅæ, Ǫ·Î¼¼¹Ìµå : ÀÌ´¢ÀÛ¿ëÀ» °¨¼Ò½Ãų ¼ö ÀÖ´Ù.
8) ¸®ÆÊÇǽÅ: Ç×°áÇÙ¼º ÀÛ¿ëÀ» °¨¼Ò½Ãų ¼ö ÀÖ´Ù.
9) ÀÓ»ó½ÃÇè¿¡¼ ¾ÆÀÚÆ¼¿ÀÇÁ¸°, 6-¸Þ¸£Ä°ÅäǪ¸° ȤÀº Ƽ¿À±¸¾Æ´Ñ°ú º´¿ë Åõ¿©½Ã, °ñ¼ö¾ïÁ¦ È¿°úÀÇ »ó½ÂÀÌ ÀÖ¾ú´Ù. »óÈ£ÀÛ¿ëÀº Á¸ÀçÇÏ´Â °ÍÀ¸·Î º¸À̳ª, ±× ±âÀü¿¡ ´ëÇØ¼± È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù. ¹éÇ÷±¸ÀÇ Á¤±âÀûÀÎ ¸ð´ÏÅ͸µÀÌ ±ÇÀåµÇ¸ç Ƽ¿ÀǪ¸°ÀÇ ¿ë¹ý¿ë·®Àº ÀÌ¿¡ µû¶ó Á¶ÀýµÇ¾î¾ß ÇÑ´Ù.
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| Á¦Çüº° º¹¾àÁöµµ |
[ÁÂÁ¦] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Mesalazine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Although the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.
|
| Pharmacology |
Mesalazine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Mesalazine (INN, BAN), also known as Mesalamine (USAN) or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism.
|
| Protein Binding |
Mesalazine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ About 80% of N-Ac-5-ASA is bound to plasma proteins, whereas 40% of mesalamine is protein bound.
|
| Half-life |
Mesalazine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.
|
| Absorption |
Mesalazine¿¡ ´ëÇÑ Absorption Á¤º¸ 20 to 30% absorbed following oral administration. 10 to 35% absorbed from the colon (rectal suppository) - extent of absorption is determined by the length of time the drug is retained in the colon.
|
| Pharmacokinetics |
MesalazineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : Á÷Àå³» Åõ¿© : ¾à 15%. ü·ù½Ã°£, º´Á¸ÇÏ´Â À§Àå°ü°è Áúȯ, ´ëÀåÀÇ pH¿¡ µû¶ó ´Ù¾çÇÏ´Ù.
- ´ë»ç : °£¿¡¼ acetyl-5-aminosalicylic acid (Ȱ¼ºÇü)·Î ¾Æ¼¼Æ¿ÈµÇ¾î glucuronide Æ÷ÇÕü·Î ´ë»çµÈ´Ù. Àå³» ´ë»çµµ ÀϾ ¼ö ÀÖ´Ù.
- ¹Ý°¨±â
- 5-ASA : 0.5-1.5 ½Ã°£
- Acetyl 5-ASA : 5-10 ½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 4-7 ½Ã°£ À̳»
- ¼Ò½Ç : ´ëºÎºÐÀÇ ´ë»çü´Â ´¢¸¦ ÅëÇØ ¹è¼³µÈ´Ù. (´ëº¯À¸·Î´Â 2% ÀÌÇÏ)
|
| Biotransformation |
Mesalazine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Rapidly and extensively metabolized, mainly to N-acetyl-5-ASA (Ac-5-ASA) in the intestinal mucosal wall and the liver. Ac-5-ASA is further acetylated (deactivated) in at least 2 sites, the colonic epithelium and the liver.
|
| Toxicity |
Mesalazine¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, mouse: LD50 = 3370 mg/kg; Oral, rat: LD50 = 2800 mg/kg; Skin, rabbit: LD50 = >5 gm/kg. There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalamine absorption from the colon is limited.
|
| Drug Interactions |
Mesalazine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Azathioprine The 5-ASA derivative increases the toxicity of thiopurineMercaptopurine The 5-ASA derivative increases the toxicity of thiopurineThioguanine The 5-ASA derivative increases the toxicity of thiopurine
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Mesalazine¿¡ ´ëÇÑ Description Á¤º¸ An anti-inflammatory agent, structurally related to the salicylates, which is active in inflammatory bowel disease. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed)
|
| Dosage Form |
Mesalazine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Enema RectalSuppository RectalSuspension RectalTablet, coated OralTablet, delayed release OralTablet, extended release Oral
|
| Drug Category |
Mesalazine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Inflammatory Agents, Non-Steroidal
|
| Smiles String Canonical |
Mesalazine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC1=CC(C(O)=O)=C(O)C=C1
|
| Smiles String Isomeric |
Mesalazine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NC1=CC(C(O)=O)=C(O)C=C1
|
| InChI Identifier |
Mesalazine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)/f/h10H
|
| Chemical IUPAC Name |
Mesalazine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 5-amino-2-hydroxybenzoic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|